首页> 外文期刊>Biomarker Insights >MicroRNA-Seq Data Analysis Pipeline to Identify Blood Biomarkers for Alzheimer's Disease from Public Data:
【24h】

MicroRNA-Seq Data Analysis Pipeline to Identify Blood Biomarkers for Alzheimer's Disease from Public Data:

机译:MicroRNA-Seq数据分析管道可从公共数据中识别阿尔茨海默氏病的血液生物标志物:

获取原文
获取外文期刊封面目录资料

摘要

BackgroundAlzheimer's disease (AD) is the most common cause of dementia with no curative therapy currently available. Establishment of sensitive and non-invasive biomarkers that promote an early diagnosis of AD is crucial for the effective administration of disease-modifying drugs. MicroRNAs (miRNAs) mediate posttranscriptional repression of numerous target genes. Aberrant regulation of miRNA expression is implicated in AD pathogenesis, and circulating miRNAs serve as potential biomarkers for AD. However, data analysis of numerous AD-specific miRNAs derived from small RNA-sequencing (RNA-Seq) is most often laborious.MethodsTo identify circulating miRNA biomarkers for AD, we reanalyzed a publicly available small RNA-Seq dataset, composed of blood samples derived from 48 AD patients and 22 normal control (NC) subjects, by a simple web-based miRNA data analysis pipeline that combines omiRas and DIANA miRPath.ResultsBy using omiRas, we identified 27 miRNAs expressed differentially between both groups, including upregulation in AD of miR-26b-3p, miR-28–3p, miR-30c-5p, miR-30d-5p, miR-148b-5p, miR-151a-3p, miR-186–5p, miR-425–5p, miR-550a-5p, miR-1468, miR-4781–3p, miR-5001–3p, and miR-6513–3p and downregulation in AD of let-7a-5p, let-7e-5p, let-7f-5p, let-7g-5p, miR-15a-5p, miR-17–3p, miR-29b-3p, miR-98–5p, miR-144–5p, miR-148a-3p, miR-502–3p, miR-660–5p, miR-1294, and miR-3200–3p. DIANA miRPath indicated that miRNA-regulated pathways potentially down– regulated in AD are linked with neuronal synaptic functions, while those upregulated in AD are implicated in cell survival and cellular communication.ConclusionsThe simple web-based miRNA data analysis pipeline helps us to effortlessly identify candidates for miRNA biomarkers and pathways of AD from the complex small RNA–Seq data.
机译:背景阿尔茨海默氏病(AD)是痴呆症最常见的病因,目前尚无治疗方法。建立能够促进AD早期诊断的敏感且非侵入性的生物标志物,对于有效施用改变疾病的药物至关重要。 MicroRNA(miRNA)介导许多靶基因的转录后抑制。 miRNA表达的异常调节与AD的发病机制有关,循环中的miRNAs作为AD的潜在生物标志物。然而,对来自小RNA测序(RNA-Seq)的许多AD特异miRNA的数据分析最费时。方法为了鉴定AD的循环miRNA生物标记物,我们重新分析了由血液样本组成的可公开获得的小RNA-Seq数据集通过将omiRas和DIANA miRPath结合在一起的简单的基于网络的miRNA数据分析管道,从48位AD患者和22位正常对照(NC)受试者中分离出结果。 -26b-3p,miR-28-3p,miR-30c-5p,miR-30d-5p,miR-148b-5p,miR-151a-3p,miR-186-5p,miR-425-5p,miR-550a -5p,miR-1468,miR-4781-3p,miR-5001-3p和miR-6513-3p以及let-7a-5p,let-7e-5p,let-7f-5p,let-的AD下调7g-5p,miR-15a-5p,miR-17-3p,miR-29b-3p,miR-98-5p,miR-144-5p,miR-148a-3p,miR-502-3p,miR-660- 5p,miR-1294和miR-3200-3p。 DIANA miRPath指出,可能在AD中下调的miRNA调控通路与神经元突触功能相关,而在AD中上调的通路与细胞存活和细胞通讯有关。结论基于Web的简单miRNA数据分析流程可帮助我们轻松识别候选物。从复杂的小RNA–Seq数据中获得miRNA生物标志物和AD通路。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号